Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 SPIE Fellow ... Physics and Optical Science and Director of the Center ... North Carolina at Charlotte, and co-founder and Chairman of ... serve as the 2015 Vice President of SPIE, the ... President Philip Stahl announced recent election results at the ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
(Date:8/28/2014)... 2014 Sterlitech is proud to announce ... its stable of products . These additional ... and include membrane filters with surface charges. ... demand for our membrane process testing equipment, and correspondingly, ... sheet membranes,” explains Sterlitech President Mark Spatz. “The ...
(Date:8/28/2014)... this month, a report was created by Colorado ... Force on the performance of vehicles using an eco-friendly, ... fuel made from mustard seeds, offered great potential as ... friendly future. In fact, every branch of the U.S. ... foreign oil over the next few years. They will ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... U.S. Asthma Control, RESEARCH TRIANGLE PARK, N.C. and ... with asthma and more than a quarter of,children with ... have their disease well controlled, according to the Asthma ... of the American,Thoracic Society meeting in Toronto., The ...
... May 20 PreViser Corporation,( http://www.previser.com ), a ... assessment technology to the dental profession,announced today the ... (OHI) Ltd ( http://www.previser.co.uk ) of Birmingham, England ... Kingdom and the,Republic of Ireland., OHI Ltd ...
... living computers by genetically altering bacteria. The findings of ... of Biological Engineering, demonstrate that computing in living cells ... applications including data storage and as a tool for ... from the biology and the mathematics departments of Davidson ...
Cached Biology Technology:Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 2Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 3PreViser and Oral Health Innovations Ltd Form UK Partnership to Provide Oral Health Scoring and Risk Analysis 2Researchers bring new meaning to the term 'computer bug' 2
(Date:8/29/2014)... University of Texas Medical Branch at Galveston has gone on ... completely protect monkeys against a lethal dose of Ebola virus ... the disease is severe. , Thomas Geisbert, professor of microbiology ... discussing advances in Ebola treatment research. The filoviruses known as ... of pathogens, with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... connections in transcription factor networks (TFNs) to evaluate the ... in PLOS Computational Biology in August. ... a network,s resilience against mutations. , "In simulations, ... models has a greater effect on robustness than varying ... Dov A. Pechenick, PhD, lead author and former researcher ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
... The most common cause of a mare,s reduced fertility is ... caused by the bacteria , Streptococcus equi subspecies ... negative for streptococci have a dormant infection without showing clinical ... to reduce the fertility of the mares," says Professor Anders ...
... Researchers at the Johns Hopkins University in Baltimore, Md., ... have found that nonself-donated cells (allografts) better survive implantation ... grafts are injected into the striatum (STR) of the ... region. In their study, all FM grafts were ...
... being passive wallflowers, are "secret gardeners" that actively engineer their ... team of scientists from Duke University and the University of ... that the distribution of plants within a marsh is a ... that,s where conditions like soil aeration and salinity best meet ...
Cached Biology News:Researchers make racehorses fertile 2Impact of stem cell transplantation location in brain a crucial factor for cell survival 2Marsh plants actively engineer their landscape 2
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Polyclonal Antibody to SHPRH...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biotin anti-mouse Ly-49C/F/I/H...
Biology Products: